RxDoctor Payments Data

Evan Lang, MD

Hematology & Oncology · Hamilton, OHNPI 1639163033

Payments from drug & device makers

$92,509in general payments, 2019–2025

Across 274 payments — averaging $337.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmacyclics LLC, An Abbvie Company$41K
  • Novartis$10K
  • Bayer$8K
  • AstraZeneca$7K
  • Blueprint Medicines Corporation$4K
  • G1 Therapeutics, Inc.$3K
  • plus $19K from 44 others

What the payments were for

  • Consulting fees$33,48164%
  • Speaking & faculty fees$10,71121%
  • Travel & lodging$1,5763%
  • Food & beverage$5,45610%
  • Education$9672%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$92,509 in reported general payments places this provider in the 70th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$3,981,558
Medicare patients
609
Services billed
150,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide49$1,084,748
Lenalidomide62$657,081
NinlaroIxazomib Citrate38$501,680
VerzenioAbemaciclib33$383,275
IbrancePalbociclib22$346,040
ImbruvicaIbrutinib25$291,917
BrukinsaZanubrutinib28$272,120
TasignaNilotinib Hcl14$268,157
InlytaAxitinib12$244,299
VenclextaVenetoclax14$204,312
RevlimidLenalidomide11$201,969
CalquenceAcalabrutinib Maleate11$170,704
EliquisApixaban198$167,777
SprycelDasatinib11$115,904
XareltoRivaroxaban111$106,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel$1,852$1,200,65260 claims
PfizerIbrance, Inlyta, Eliquis$121$758,117232 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$198$501,68038 claims
Lilly USA, LLCVerzenio$23$383,27533 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$40,881$291,91725 claims
Beigene USA, Inc.Brukinsa$2,177$272,12028 claims
NovartisTasigna$9,531$268,15714 claims
AbbVieVenclexta$173$204,31214 claims
Bristol Myers SquibbRevlimid$1,580$201,96911 claims
AstraZenecaCalquence$7,203$170,70411 claims
Johnson & JohnsonXarelto$1,177$106,276111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Hamilton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →